QuantHealth Secures $17M Funding to Revolutionize Clinical Trials with AI

Date:

QuantHealth, an AI-powered clinical trial design company, has recently secured $17 million funding in its latest investment round, aiming to revolutionize clinical trials through the use of artificial intelligence. The funding includes a strategic investment from Accenture Ventures, as well as participation from a prominent contract research organization (CRO) firm and other investors.

The additional funding brings QuantHealth’s total Series A round to $17 million, providing the company with the resources to enhance its platform used by pharmaceutical and biotech companies. The platform is designed to save millions on clinical trials and drug development processes.

QuantHealth’s simulation platform utilizes proprietary AI technology that has been trained on a massive dataset of 350 million patients, along with large biomedical knowledge graphs and clinical trial data. Through this advanced technology, the platform can predict trial outcomes with an impressive 86% accuracy rate on the binary endpoint metric.

By simulating thousands of protocol variations, QuantHealth’s platform has the ability to discover the optimal trial design for success. This helps research and development (R&D) teams in the pharmaceutical and biotech industries to more accurately and rapidly develop and optimize trial protocols.

Clinical trials are highly expensive endeavors, often costing billions of dollars to execute. Unfortunately, less than 10% of drugs that undergo clinical trials make it to market. Additionally, trial failures result in an estimated $50 billion in losses annually, which accounts for roughly 20% of the global pharmaceutical R&D budget. Many of these failures can be attributed to the lack of a proper drug-population fit and drug-protocol fit.

See also  IonQ Aims to Achieve Human-Level Quantum Machine Learning with Revolutionary Advancements in AI

QuantHealth’s platform seeks to address these challenges by simulating trials at scale, effectively lowering risks and expediting the drug development process. The company currently collaborates with several global pharmaceutical firms to leverage its product in clinical trial design and development.

This recent funding announcement follows QuantHealth’s $15 million Series A funding round, which was co-led by Bertelsmann Investments and Pitango HealthTech. Existing investors, including Shoni Top Ventures and Nina Capital, also participated in the funding round.

To complement the funding, QuantHealth has also launched its latest product, Katina. This AI-guided workflow tool provides clinical researchers with the ability to simulate hundreds of thousands of potential trial protocol combinations. By considering various patient groups, treatment parameters, and different endpoints, Katina aims to maximize the probability of trial success.

Orr Inbar, co-founder and CEO of QuantHealth, expressed excitement about the investment and emphasized the potential of AI to transform the clinical trial landscape. He stated, We’re able to seamlessly integrate data and cloud technology into the clinical trial process, not only saving time and money for pharmaceutical companies but also increasing the chance of success in drug development. Accenture’s long-standing experience in this industry and leadership in data and AI will help us continue to scale our platform globally.

QuantHealth’s funding and product launch demonstrate the growing importance of AI in revolutionizing the clinical trial process. By leveraging advanced technologies and data-driven insights, the company is positioning itself as a leading player in enhancing the efficiency, accuracy, and success rates of clinical trials, ultimately benefitting the pharmaceutical and biotech industries as a whole.

See also  AI System 'Dora' Enhances Patient Care Post-Cataract Surgery - Study Finds

Disclaimer: This article is generated by OpenAI’s language model.

Frequently Asked Questions (FAQs) Related to the Above News

What is QuantHealth?

QuantHealth is an AI-powered clinical trial design company that aims to revolutionize the clinical trial process through the use of artificial intelligence.

How much funding did QuantHealth secure in its recent investment round?

QuantHealth secured $17 million funding in its latest investment round. This includes a strategic investment from Accenture Ventures, as well as participation from a prominent contract research organization (CRO) firm and other investors.

How does QuantHealth's platform work?

QuantHealth's platform utilizes proprietary AI technology trained on a massive dataset of 350 million patients, along with large biomedical knowledge graphs and clinical trial data. It simulates thousands of protocol variations to discover the optimal trial design for success.

What is the accuracy rate of QuantHealth's platform in predicting trial outcomes?

QuantHealth's platform boasts an impressive 86% accuracy rate on the binary endpoint metric.

What problem does QuantHealth's platform aim to address?

QuantHealth's platform aims to address the challenges faced in clinical trials, including the high costs and low success rates. It focuses on improving the drug-population fit and drug-protocol fit by simulating trials at scale.

What is the estimated cost of trial failures annually?

Trial failures result in an estimated $50 billion in losses annually, which accounts for roughly 20% of the global pharmaceutical R&D budget.

Which companies does QuantHealth currently collaborate with?

QuantHealth currently collaborates with several global pharmaceutical firms to leverage its platform in clinical trial design and development.

What is Katina?

Katina is QuantHealth's latest product, an AI-guided workflow tool that allows clinical researchers to simulate hundreds of thousands of potential trial protocol combinations. It aims to maximize the probability of trial success by considering various patient groups, treatment parameters, and different endpoints.

Who led QuantHealth's previous funding round?

QuantHealth's previous funding round was co-led by Bertelsmann Investments and Pitango HealthTech.

How does QuantHealth plan to scale its platform globally?

QuantHealth plans to scale its platform globally with the help of Accenture's long-standing experience in the industry, as well as its leadership in data and AI.

How does QuantHealth's funding and product launch contribute to the clinical trial landscape?

QuantHealth's funding and product launch highlight the growing importance of AI in revolutionizing the clinical trial process. By leveraging advanced technologies and data-driven insights, QuantHealth aims to enhance the efficiency, accuracy, and success rates of clinical trials, benefiting the pharmaceutical and biotech industries as a whole.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.